Merck

Apr 30, 2020

Remdesivir of Gilead accelerates COVID-19 recovery Gilead Sciences' Remdesivir shows the first data from a placebo-controlled study. Remdesivir decreases recovery time for hospitalized COVID-19 patients by four days or 31% as published in a National Institutes of Health-sponsored study setting the drug against p...

Apr 28, 2020

Merck has collaborated with the Seattle-based Institute for Systems Biology (ISB) to further study novel coronavirus SARS-CoV-2. The primary goal of the collaboration will be to investigate the molecular pathway of SARS-CoV-2 and aetiology of COVID-19 with the intent of finding an effective and standard treatm...

Jan 07, 2020

A South Korean startup therapeutics company Nunaps has successfully raised USD 4.2 Million around 5 billion won in a Series A round.  The investment was made by the K Partners, KTB Network, and K2 Investment Partners. Nunaps is digital therapeutics and is planning to use the funds to build its digital thera...

Dec 24, 2019

Roche has entered into a licensing partnership with Sarepta Therapeutics worth USD 1.15 Billion.  Roche has agreed to license in Sarepta’s gene therapy ‘SRP-9001’ for Duchenne muscular dystrophy (DMD), though which Roche will gain access to exclusive rights to it globally except in the US.  As per t...

Dec 10, 2019

Merck is set to complete the already planned purchase of the ArQule for USD 2.7 Billion. Under the terms of the agreement, Merck will pay USD 20 for each share in cash for a total amount of USD 2.7 Billion. ArQule is a biopharmaceutical, which is focused on kinase inhibitor discovery, finding cures for cancer p...

Dec 02, 2019

When cough seems everlasting, mortifying, and excruciating, it is high time to consult a physician as you might be stricken by chronic cough, which can be irritating and may also lead to nagging cough and a throbbing headache. Although chronic cough is not usually severe, it can be very annoying. Chronic Refractory...

Aug 22, 2019

Themis Bioscience forms an Exclusive License and Research Alliance with MSD to Develop Vaccines Themis Bioscience, a vaccine development firm, has collaborated with the MSD, a trademark company of the Merck. The agreement is an exclusive license with MSD for the discovery and development of measles vaccines to f...

Jun 13, 2019

Telegenomics Company Genome Medical nets USD 23 M Genome Medical, a telegenomics company, having expertise in delivering genome-based medicine has raised USD 23 Million in series B funding.  The proceeds will be used by the company to accelerate the development of its technology and medical services to supp...

May 23, 2019

Merck decides to acquire Peloton Therapeutics, fortifying Oncology pipeline Merck is ready to buy Peloton Therapeutics for USD 1.1 million. The companies have entered into a definitive agreement which will give Merck rights over an oral HIF-2α inhibitor- PT2977, which is Peloton’s lead candidate for the treatme...

May 02, 2019

EISAI now solely responsible for lemborexant Eisai today announced that its U.S. subsidiary has bought out  Purdue Pharma L.P.’s rights in the worldwide collaboration for the development and commercialization of lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multip...